Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
12:00pm, Monday, 26'th Aug 2024
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contender
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
08:00am, Friday, 23'rd Aug 2024
Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that o
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
09:20am, Thursday, 22'nd Aug 2024
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide Select DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
07:00am, Thursday, 22'nd Aug 2024
CBeyond™ will assess nimacimab's ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab CBeyond™ will assess nimacimab's ability to s
Viking Therapeutics could be a new winner in the GLP-1 space
05:30pm, Wednesday, 21'st Aug 2024
GLP-1 weight-loss drugs have taken the pharmaceutical world by storm, Novo Nordisk (NVO) and Eli Lilly (LLY) making a name for the class of drugs through their own landmark brands. But what about the
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
09:00am, Wednesday, 21'st Aug 2024
DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutide Select DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks KELOWNA, B
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
11:20pm, Tuesday, 20'th Aug 2024
Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company deve
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
06:12am, Sunday, 18'th Aug 2024
The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
07:21am, Saturday, 17'th Aug 2024
Eli Lilly's sales grew by 36% last quarter, largely due to the success of two products. The company has a promising molecule, tirzepatide, which has shown that it can help people lose significant weig
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
08:00am, Thursday, 15'th Aug 2024
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,
What Eli Lilly, Novo Nordisk earnings show about GLP-1 sales
01:07pm, Friday, 09'th Aug 2024
Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created equal. Yahoo Finance senior healthcare repor
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's he
Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earnings
06:37pm, Thursday, 08'th Aug 2024
Shares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The pharmaceutical giant raised its revenue outlo
